The design and evaluation of HIV-1 vaccines (Q38019332)

27 August 2017

title

The design and evaluation of HIV-1 vaccines (English)

1 reference

27 August 2017

1 reference

3

Gary J Nabel

1 reference

27 August 2017

Kevin O Saunders

1

1 reference

27 August 2017

Rebecca S Rudicell

series ordinal

2

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 June 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

26

1 reference

27 August 2017

issue

10

1 reference

27 August 2017

page(s)

1293-1302

1 reference

Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors

27 August 2017

cites work

1 reference

12 December 2020

Rational modifications of HIV-1 envelope glycoproteins for immunogen design

1 reference

12 December 2020

Timing the ancestor of the HIV-1 pandemic strains

1 reference

12 December 2020

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys

1 reference

12 December 2020

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

1 reference

12 December 2020

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

12 December 2020

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins

1 reference

12 December 2020

Novel adenovirus vector-based vaccines for HIV-1.

1 reference

12 December 2020

Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency

1 reference

12 December 2020

HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine

1 reference

12 December 2020

HIV vaccine design and the neutralizing antibody problem

1 reference

12 December 2020

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

1 reference

12 December 2020

Strategies for eliciting HIV-1 inhibitory antibodies

1 reference

12 December 2020

Antibody-based protection against HIV infection by vectored immunoprophylaxis

1 reference

12 December 2020

HIV vaccine design: insights from live attenuated SIV vaccines

1 reference

12 December 2020

Fc receptor-mediated antiviral antibodies

1 reference

12 December 2020

The multifactorial nature of HIV-1 latency

1 reference

12 December 2020

Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

1 reference

12 December 2020

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

12 December 2020

Progress in the rational design of an AIDS vaccine

1 reference

12 December 2020

Vaccine design for CD8 T lymphocyte responses

1 reference

12 December 2020

Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells

1 reference

12 December 2020

SIVmac251 is inefficiently transmitted to rhesus macaques by penile inoculation with a single SIVenv variant found in ramp-up phase plasma

1 reference

12 December 2020

Immunization against AIDS in humans

1 reference

12 December 2020

Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies.

1 reference

12 December 2020

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

1 reference

12 December 2020

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector

1 reference

12 December 2020

Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.

1 reference

12 December 2020

Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine

1 reference

12 December 2020

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

1 reference

12 December 2020

Control of HIV-1 replication in elite suppressors

1 reference

12 December 2020

The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection

1 reference

12 December 2020

Modifications of HIV-1 retrovirus-like particles to enhance safety and immunogenicity

1 reference

12 December 2020

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

1 reference

12 December 2020

Broad HIV-1 neutralization mediated by CD4-binding site antibodies

1 reference

12 December 2020

An effective HIV vaccine: A combination of humoral and cellular immunity?

1 reference

12 December 2020

Immunologic considerations for generating memory CD8 T cells through vaccination.

1 reference

12 December 2020

Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis

1 reference

12 December 2020

Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.

1 reference

12 December 2020

A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251.

1 reference

12 December 2020

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

1 reference

12 December 2020

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

1 reference

12 December 2020

Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection

1 reference

12 December 2020

The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors

1 reference

12 December 2020

Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1.

1 reference

12 December 2020

The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

1 reference

12 December 2020

The antigenic structure of the HIV gp120 envelope glycoprotein

1 reference

12 December 2020

Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer

1 reference

12 December 2020

The immune response during acute HIV-1 infection: clues for vaccine development

1 reference

12 December 2020

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

1 reference

12 December 2020

Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility

1 reference

12 December 2020

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

1 reference

12 December 2020

HIV vaccine development--improving on natural immunity

1 reference

12 December 2020

Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial.

1 reference

12 December 2020

The Antibody Response against HIV-1

1 reference

12 December 2020

DNA vaccination for HIV-1 and SIV.

1 reference

12 December 2020

Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef

1 reference

12 December 2020

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

1 reference

12 December 2020

Structural definition of a conserved neutralization epitope on HIV-1 gp120

1 reference

12 December 2020

Moving ahead an HIV vaccine: use both arms to beat HIV

1 reference

12 December 2020

Elicitation of structure-specific antibodies by epitope scaffolds

1 reference

12 December 2020

Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.

1 reference

12 December 2020

Immune responses to adenovirus and adeno-associated virus in humans.

1 reference

12 December 2020

Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination

1 reference

12 December 2020

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

1 reference

12 December 2020

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection

1 reference

12 December 2020

Predictive value of primate models for AIDS.

1 reference

12 December 2020

Viral Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in Clinical Trials of HIV‐1 Vaccine Candidates

1 reference

12 December 2020

Stable antibody expression at therapeutic levels using the 2A peptide

1 reference

12 December 2020

Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239

1 reference

12 December 2020

Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers

1 reference

12 December 2020

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

1 reference

12 December 2020

Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys

1 reference

12 December 2020

Molecular architecture of native HIV-1 gp120 trimers

1 reference

12 December 2020

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

1 reference

12 December 2020

From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice

1 reference

12 December 2020

HIV vaccines: progress to date.

1 reference

12 December 2020

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

1 reference

12 December 2020

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

1 reference

12 December 2020

Prevention of HIV-1 infection with early antiretroviral therapy

1 reference

12 December 2020

HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals

1 reference

12 December 2020

Is developing an HIV-1 vaccine possible?

1 reference

12 December 2020

Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope

1 reference

12 December 2020

HIV vaccines: lessons learned and the way forward

1 reference

12 December 2020

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

1 reference

12 December 2020

Estimating the benefit of an HIV-1 vaccine that reduces viral load set point

1 reference

12 December 2020

Poxvirus vector-based HIV vaccines

1 reference

12 December 2020

Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

1 reference

12 December 2020

HIV vaccine research in Thailand: lessons learned

1 reference

12 December 2020

Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans

1 reference

12 December 2020

Functional and phenotypic characterization of the humanized BLT mouse model

1 reference

12 December 2020

Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region

1 reference

12 December 2020

Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response

1 reference

12 December 2020

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

1 reference

12 December 2020

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

1 reference

12 December 2020

HIV-1 vaccines and adaptive trial designs

1 reference

12 December 2020

A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.

1 reference

12 December 2020

Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.

1 reference

12 December 2020

Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

1 reference

12 December 2020

Broad neutralization coverage of HIV by multiple highly potent antibodies

1 reference

12 December 2020

Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies

1 reference

12 December 2020

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene

1 reference

12 December 2020

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

1 reference

12 December 2020

Rational antibody-based HIV-1 vaccine design: current approaches and future directions

1 reference

12 December 2020

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

1 reference

12 December 2020

10.1097/QAD.0B013E32835474D2

Identifiers

DOI

1 reference

release_qxri5t5d5ndv3lobkdop27klyu

27 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qxri5t5d5ndv3lobkdop27klyu

24 November 2022

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/qxri5t5d5ndv3lobkdop27klyu

24 November 2022

mapped directly with Wikidata item

1 reference